Objective: The purpose of this study was to clarify the role of glycoxidation and lipid peroxidation of low-density lipoprotein (LDL) in e atherogenesis. Methods and results: We examined the formation of N -(carboxymethyl) lysine (CML), a glycoxidation product, and malondialdehyde (MDA), a lipid peroxidation product, in vitro and their co-localization in human atherosclerotic lesions. Immunochemical analysis revealed that CML was formed in a time-dependent manner by human LDL incubated with copper ions and glucose, i.e. an in vitro model of glycoxidation of LDL. When LDL was exposed to copper ions alone, a small amount of CML was formed, however this was significantly less in oxidized LDL than glycoxidative LDL. In contrast, MDA formation was observed in both oxidation and glycoxidation of LDL, but not in glycation of LDL. Hexitol-lysine (HL), an Amadori product, was formed by both glycation and glycoxidation of LDL, but not by oxidation of LDL. Immunohistochemical analysis showed that CML and MDA accumulated mainly in macrophage / foam cells, while pyrraline, a non-oxidative product of glycation, and apolipoprotein B were localized in the extracellular matrix in atherosclerotic lesions. Atheromas were positive for CML and MDA, but negative for pyrraline. Macrophage / foam cells in atherosclerotic lesions exhibited co-localization of macrophage scavenger receptor-A with CML and MDA, but not with pyrraline. Conclusion: Our results suggest that glycoxidation and lipid peroxidation of LDL synergistically promote the development of atherosclerotic lesions through interaction with macrophage scavenger receptor-A.
Introduction
glycation end-products (AGEs), which comprise heterogeneous chemical compounds [1] . We have previously dem-A series of non-enzymatic chemical reactions between onstrated that AGEs accumulate in human atherosclerotic reducing sugars, proteins and lipids generate Amadori lesions and that their location depends on different epiproducts and eventually lead to formation of advanced topes on AGEs [2] . Palinski et al. [3] demonstrated colocalization of oxidation-specific adducts and AGE-specific epitopes within intimal lesions of euglycemic WHHL rabbits. Thus, in vivo lipid peroxidation and glycation in atherogenesis. However, the respective roles of these cose were obtained from Wako (Osaka, Japan). Crysmetabolic factors in atherogenesis are not clearly estabtallized bovine serum albumin (BSA) was purchased from lished.
Seikagaku Kogyo (Tokyo, Japan). The BCA protein assay e N -(carboxymethyl)lysine (CML) and pentosidine are kit was purchased from Pierce (Rockford, IL). Non-immajor chemical compounds in AGEs, which form under mune, chromatographically-purified rabbit and mouse IgG oxidative conditions, and are referred to as glycoxidation were obtained from Zymed (San Francisco, CA). A 96-products [4] . Previous studies have shown the presence of well microtitration plate was purchased from Greiner high levels of glycoxidation and lipid peroxidation prod-(Frickenhausen, Germany). All other chemicals were of ucts in serum and tissues in association with atherothe best grade available from commercial sources. sclerosis, diabetes and aging [4] [5] [6] . Glycated LDL is more susceptible to oxidative modification of its lipids and 2.2. Antibodies protein than native LDL, suggesting the contribution of glycoxidation to oxidized LDL formation [7, 8] . Amadori Horseradish peroxidase (HRP)-conjugated rabbit antiproducts and intermediates are known sources of reactive mouse IgG antibody was purchased from Cappel (Durham, oxygen species, such as superoxide and hydrogen peroxide NC). Monoclonal anti-asmooth muscle actin antibody, [9,10], which are likely to be involved in glycoxidationmonoclonal anti-human macrophage antibody (CD68), induced enhancement of oxidized modification of LDL. In biotinylated rabbit anti-mouse IgG antibody, HRP-conjuour previous studies [2, 11, 12] , macrophage / foam cells in gated goat anti-rabbit IgG antibody and alkaline phosatherosclerotic lesions exhibited co-localization of CML phatase-labeled streptavidin were obtained from Dako and oxidized phosphatidylcholine, which is thought to be (Carpinteria, CA). Biotinylated goat anti-mouse IgG1IgM an early product of oxidative modification of phospholipid antibody was obtained from Chemicon (Temecula, CA). on LDL. However, the staining pattern of these two HRP-conjugated goat anti-mouse IgG1IgM antibody was compounds was somewhat different in the extracellular obtained from Jackson ImmunoRes (West Grove, PA). matrix of the intima. Malondialdehyde (MDA) is known to Monoclonal anti-human apolipoprotein B (Apo-B) antibe an end-product of lipid peroxidation formed by oxidabody was obtained from Monosan (The Netherlands). A tion of LDL [13] . Moreover, MDA-modified LDL has been monoclonal antibody against oxidized LDL (DLH2) was shown to increase in serum and tissues in association with prepared as described by Itabe et al. [20] . This antibody atherogenesis [14, 15] . Therefore, we examined CML and recognizes various proteins modified by malondialdehyde MDA formation by in vitro glycoxidation and oxidation of (MDA), including MDA-LDL, MDA-BSA, MDA-high-LDL, and their immunohistochemical localization in density lipoprotein and MDA-hemoglobin [20] . Monoatherosclerotic lesions.
clonal anti-CML and pyrraline (PRL) antibodies were Macrophages and macrophage-derived foam cells play prepared by Horiuchi et al., as previously described an important role in atherogenesis. These cells express [21, 22] . The polyclonal anti-hexitol-lysine (HL) and monovarious scavenger receptors to bind and internalize clonal anti-macrophage scavenger receptor-A (SRA-E5) negatively-charged macromolecules, including acetylated antibodies were prepared as described by Myint et al. buffer (pH 7.4). Glycated LDL (gl-LDL) was prepared by incubation of n-LDL with 250 mM glucose in the presence Sections of arterial walls were obtained from ten males of 1 mM EDTA and 1 mM DTPA. Glycoxidative modiand ten females at autopsy within 6 h of death (mean age, fication of LDL (go-LDL) was performed by incubating 58.5613.9 years; range, 31-84 years). Table 1 lists the n-LDL with both 5 mM CuSO and 250 mM glucose in 0.2 cause of death in each subject. All subjects were both 4 M phosphate buffer (pH 7.4). Non-glycated / non-oxidized clinically and pathologically free of diabetes mellitus and LDL (ngo-LDL) was prepared by incubating n-LDL in 0.2 chronic renal failure. As shown in Table 1 , samples for M phosphate buffer (pH 7.4) containing 1 mM EDTA / 1 immunohistochemical analysis comprised 28 grossly normM DTPA. The modification was stopped by extensive mal regions (diffuse intimal thickening, DIT), 24 fatty dialysis of the reaction mixtures against 0.15 M NaCl and streaks (FS) and 23 atherosclerotic plaques (AP). Compli-0.25 mM EDTA at 48C. Protein concentration was decated lesions with calcification and ulceration were extermined using the BCA protein assay kit.
cluded from the study. Tissue specimens were washed with PBS and then fixed with Carnoy's fixative for 2 h. After 2.5. Quantification of CML, HL and MDA formation by dehydration with ethanol, tissues were embedded in parafnon-competitive ELISA fin. Paraffin sections were prepared and stained with hematoxylin and eosin. The formation of CML, HL and MDA was estimated using non-competitive ELISA. All procedures were carried 2.8. Immunohistochemical methods out at room temperature. The wells of microtiter plates were coated with various concentrations of samples in 0. 1 Immunohistochemical localization of various antigens, ml carbonate buffer for 60 min. For HL assay, samples including CML, MDA, PRL and Apo-B, was examined were diluted with PBS (pH 7.4) and simultaneously using the labeled streptavidin-biotin technique. Briefly, reduced by adding 0.1 M NaBH solution [23] . Wells were serial tissue sections were deparaffinized and then subject- 4 washed three times with wash buffer (PBS containing ed to protease pretreatment at room temperature for 10 min 0.05% Tween 20), and then incubated with 0.5% gelatin for CML and PRL. After treatment with 3% BSA for 30 for 60 min to block non-specific binding. After washing min, the slides were reacted with primary antibody at 48C again with wash buffer, 50 ml of anti-CML, anti-MDA or overnight. The primary antibodies used in this study anti-HL antibody in PBS containing 0.1% BSA and 0.05% included monoclonal anti-CML (6D12), anti-PRL (H12) Tween 20 was added to each well and incubated for 60 anti-MDA (DLH2) and anti-Apo-B antibodies, as well as min. After further washings, the wells were incubated with monoclonal anti-asmooth muscle actin and anti-human 50 ml peroxidase-conjugated second antibody for 60 min. macrophage (CD68) antibodies. 2 ). The reaction mixture contained levamisole (24 mg / ml) to block endogenous alkaline phosphatase activity. Incubation of n-LDL with copper ions and glucose was After washing with PBS, sections were counterstained with carried out at 378C for 2 weeks in the presence or absence Meyer hematoxylin. Control tests for specificity of imof metal chelators, including EDTA (1 mM) and DTPA (1 munostaining included substitution of non-immune sera or mM), and aminoguanidine (100 mM). After extensive PBS for primary antibodies and competitive test with dialysis against PBS containing 0.25 mM EDTA, we antibodies preincubated with excess of CML-bovine serum determined the formation of CML, HL and MDA using albumin, MDA-LDL or synthesized pyrraline. To evaluate non-competitive ELISA, as described. The inhibitory effect the interaction between macrophages and modified LDL, of chelators and aminoguanidine was expressed as the co-localization of macrophage scavenger receptor-A with percentage decrease in absorbance at 492 nm (% inhibi-CML, MDA and PRL in atherosclerotic lesions was tion): % inhibition51003[(ABSa2ABSb) /(ABSc2 assessed using an immunohistochemical double-staining technique. In the first step, deparaffinized sections were (oxidized or glycated LDL) showed no increase in imstained with monoclonal anti-macrophage scavenger remunoreactivity to anti-CML antibody. LDL incubated with ceptor-A antibody (SRA-E5). After visualization of percopper ions for 2 weeks formed CML to some extent, oxidase activity localization with 3,39diaminobenzidine as however the amount was significantly smaller than glycoxa substrate, sections were rinsed with 0.1 M glycine-HCl idative LDL. As shown in Fig. 1B , LDLs incubated with buffer (pH 2.2) for 60 min. In the second step, the same copper ions or copper ions and glucose, i.e. oxidized and sections were incubated with anti-CML, anti-MDA or glycoxidative LDLs, significantly increased the immunoanti-PRL antibody. The alkaline phosphatase coloring reactivity to anti-MDA antibody after 1 and 2 weeks. No reaction was performed as described before.
difference in the intensity of immunoreactivity to anti-MDA antibody was observed between oxidized and 2.9. Statistical analysis glycoxidative LDLs. In contrast, glycation of LDL did not lead to MDA formation. Fig. 1C shows HL formation in Numerical data were expressed as mean6S.D. In vitro various modified LDLs. Significant formation of HL was data showed a normal distribution. In consequence, differobserved in both glycated and glycoxidative LDLs after 1 ences between groups were examined for statistical signifiand 2 weeks. The intensity of immunoreactivity of cance by using Student's unpaired t-test. P-values of less glycated LDL with anti-HL antibody was similar to that of than 0.05 were considered significant. glycoxidative LDL after 1 and 2 weeks. In contrast, oxidized LDL exhibited no HL formation.
Results

Effects of chelators and aminoguanidine on the formation of CML, HL and MDA
Formation of CML, MDA and HL in low-density lipoprotein by glycation, oxidation and glycoxidation
Next, we examined the effects of chelators and aminoguanidine on the formation of CML, HL and MDA, to Fig. 3A and B) . Staining of serial lesions sections with antibody against macrophage marker CD68 confirmed that the foam cells were macrophage-derived Fig. 2 shows the immunohistochemical localization of (Fig. 3E) . A proportion of smooth muscle cells was also CML and pyrraline (PRL) in diffuse intimal thickening positive for CML and MDA. In contrast, PRL and Apo-B (DIT). CML was found in a few smooth muscle cells and were found exclusively in extracellular matrix in FS ( 3C and D). Fig. 4 shows representative immunohisto-E, most of the CD68-positive foam cells in atherosclerotic chemical localization of various antigens in atheromatous lesions expressed scavenger receptor-A. The cytoplasm of plaques (AP). CML and MDA were observed in both these foam cells was also positive for CML and MDA macrophage / foam cells and smooth muscle cells, and also ( Fig. 5A and B) . MDA was also detected in smooth in extracellular matrix and atheromas (Fig. 4A, B, D and muscle cells, which were negative for CD68 and SRA-E5. E). In contrast, PRL and Apo-B were sparse in macroIn contrast, PRL was detected in the extracellular matrix, phage / foam cells and smooth muscle cells, but were but not in foam cells expressing macrophage scavenger detected in the extracellular matrix of AP (Fig. 4C, F and receptor-A (Fig. 5C ). G). CML and MDA, but not PRL, were found in atheromas in most AP (Fig. 4A, B and C) .
Discussion
Co-localization of macrophage scavenger receptors with CML, MDA and PRL
Non-enzymatic glycation between reducing sugars and proteins produces Amadori compounds and, subsequently, We used the double-staining method to illustrate the leads to formation of AGEs. Recent studies have shown interaction between macrophage scavenger receptors and that AGEs are generated via both oxidative and nonglycoxidative and oxidized LDL. As shown in Fig. 5D and oxidative pathways. CML is an oxidative AGE, i.e. a glycoxidation product, and is found in a variety of tissues, which was also inhibited by |67% by aminoguanidine. HL including aorta, kidney, lens crystalline and collagen formation was not inhibited by chelators or amino- [22, 25, 26] . Malondialdehyde (MDA) is an end-product of guanidine. Thus, the present study established an in vitro lipid peroxidation reactions and is well characterized model of LDL glycoxidation, which was characterized by during oxidation of polyunsaturated fatty acids on LDL CML formation. [13] . There are reports of enhancement of both oxidation CML is known to accumulate in macrophage / foam cells and AGE-modification of LDL in diabetic patients [27, 28] .
and smooth muscle cells in atherosclerotic lesions [12, 31] . Glycation has been shown to enhance LDL oxidation and
We previously demonstrated that oxidized phosphatidylcontribute to accelerated atherosclerosis in diabetic patients choline, another lipid peroxidation product, co-localize [29, 30] . However, glycoxidative LDL has not been well with CML in macrophage / foam cells in atherosclerotic characterized. In this in vitro study, we showed that MDA lesions [12] . However, the distribution of CML and was formed in LDL incubated with copper ions in the oxidized phosphatidylcholine was different in extracellular presence or absence of glucose, whereas CML was formed matrix of intima. Atheromas were positive for CML, but exclusively in LDL incubated with both copper ions and negative for oxidized phosphatidylcholine. The present in glucose. Although CML was formed in LDL incubated vivo study demonstrated co-localization of CML and MDA with copper ions for 2 weeks, the amount was significantly in macrophage / foam cells and smooth muscle cells, consmaller than that formed by glycoxidative LDL. HL, an sistent with results of previous studies from our labAmadori product, was formed by glycated and glycoxidaoratories [11, 12, 31] . Moreover, both CML and MDA tive LDLs, but not by oxidized LDL. Moreover, CML accumulated in atheromas. In contrast, pyrraline, a nonformation in glycoxidative LDL was completely inhibited oxidative AGE, and apolipoprotein B, were found excluby both chelators and aminoguanidine. However, chelators sively in extracellular matrix in the intima. Atheromas completely blocked MDA formation in glycoxidative LDL, were negative for pyrraline. These results indicate that 
